Rezetamig Biosimilar – Anti-Sialic acid-binding Ig-like lectin 2; T-cell surface glycoprotein CD3 epsilon chain mAb – Research Grade

Description of Rezetamig Biosimilar - Anti-Sialic acid-binding Ig-like lectin 2; T-cell surface glycoprotein CD3 epsilon chain mAb - Research Grade

Introduction:

Rezetamig Biosimilar is a monoclonal antibody (mAb) that targets the T-cell surface glycoprotein CD3 epsilon chain, also known as CD3e. This antibody is a biosimilar version of the anti-sialic acid-binding Ig-like lectin 2 (Siglec-2) mAb, which is commonly used as a therapeutic target for various diseases.

Structure of Rezetamig Biosimilar:

Rezetamig Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL2) and one variable domain (VL). The VH and VL domains together form the antigen-binding site of the antibody, which specifically recognizes and binds to the CD3e protein.

Activity of Rezetamig Biosimilar:

Rezetamig Biosimilar works by binding to the CD3e protein on the surface of T-cells. This binding triggers a series of signaling events that activate the T-cells, leading to their proliferation and differentiation. This activation of T-cells is crucial for the immune response against pathogens and abnormal cells in the body.

In addition to its role in activating T-cells, Rezetamig Biosimilar also has the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This means that the antibody can bind to target cells and recruit immune cells, such as natural killer cells, to kill the target cells. This mechanism of action makes Rezetamig Biosimilar an effective therapeutic agent for diseases that involve abnormal or cancerous cells.

Application of Rezetamig Biosimilar:

Rezetamig Biosimilar has been approved for the treatment of various diseases, including B-cell lymphomas, leukemias, and autoimmune disorders. In B-cell lymphomas and leukemias, the CD3e protein is overexpressed on the surface of the cancerous cells, making them a suitable target for Rezetamig Biosimilar. By binding to the CD3e protein, the antibody can activate T-cells and induce ADCC, leading to the destruction of the cancer cells.

In autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, T-cells play a crucial role in the disease pathogenesis. By targeting the CD3e protein, Rezetamig Biosimilar can modulate the activity of T-cells and suppress the immune response, thereby reducing inflammation and disease progression.

Research Grade Rezetamig Biosimilar:

Apart from its therapeutic applications, Rezetamig Biosimilar is also available in a research grade form. This means that the antibody is produced and purified to a high degree of purity and is suitable for use in various research applications, such as flow cytometry, immunohistochemistry, and western blotting. The research grade form of Rezetamig Biosimilar is commonly used by scientists to study the role of CD3e in various diseases and to develop new treatments targeting this protein.

Conclusion:

Rezetamig Biosimilar is a recombinant humanized monoclonal antibody that specifically targets the CD3e protein on the surface of T-cells. Its ability to activate T-cells and induce ADCC makes it an effective therapeutic agent for various diseases, including B-cell lymphomas, leukemias, and autoimmune disorders. In addition, the research grade form of Rezetamig Biosimilar is widely used by scientists to study the role of CD3e in disease and to develop new treatments. Overall, Rezetamig Biosimilar is a promising antibody with a wide range of applications in both research and therapy.